ReviewJournal of thrombosis and thrombolysis2020
Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic.
Review in Journal of thrombosis and thrombolysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Effect of anticoagulation on the incidence of venous thromboembolism, major bleeding, and mortality among hospitalized COVID-19 patients: an updated meta-analysis.Frontiers in cardiovascular medicine · 2024Pooled it
- Meta-analysis of coagulation parameters associated with disease severity and poor prognosis of COVID-19.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020Pooled it
- Article
- The association between prolonged lymphopenia and in-hospital venous thromboembolism among different respiratory virus infections: a retrospective cohort study.Research and practice in thrombosis and haemostasis · 2025Article
- Thromboprophylaxis in Pregnant Women with COVID-19: An Unsolved Issue.International journal of environmental research and public health · 2023Review
- Animal Models of COVID-19 II. Comparative Immunology.ILAR journal · 2021Review
- Validation of a Prognostic Score to Identify Hospitalized Patients with COVID-19 at Increased Risk for Bleeding.Viruses · 2021Article
- Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic.Current hematologic malignancy reports · 2021Review
- Should we screen Eastern Mediterranean COVID-19 patients for inherited thrombophilia?Medical hypotheses · 2021Article
- Malfunctioning temporary hemodialysis catheters in patients with novel coronavirus disease 2019.Journal of vascular surgery · 2021Article
- Acute Pulmonary Embolism in Patients with and without COVID-19.Journal of clinical medicine · 2021Article
- Prioritizing studies of COVID-19 and lessons learned.Journal of clinical and translational science · 2021Article
- COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis.Journal of thrombosis and thrombolysis · 2021Observational
- Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?International journal of hematology · 2021Review
- Acute confusional state as a prognostic sign of COVID-19 large-vessel occlusion (LVO).BMJ case reports · 2021Article
- Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19.Blood cancer journal · 2021Article
- Treatment of COVID-19 patients with quercetin: a prospective, single center, randomized, controlled trial.Turkish journal of biology = Turk biyoloji dergisi · 2021Article
- Practical Recommendations for the Management of Patients with ITP During the COVID-19 Pandemic.Mediterranean journal of hematology and infectious diseases · 2021Review
- D-Dimers Level as a Possible Marker of Extravascular Fibrinolysis in COVID-19 Patients.Journal of clinical medicine · 2020Article
- [COVID-19 and venous thromboembolism].Annales de cardiologie et d'angeiologie · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A common and potent consideration has recently entered the landscape of the novel coronavirus disease of 2019 (COVID-19): venous thromboembolism (VTE). COVID-19 has been associated to a distinctive related coagulopathy that shows unique characteristics. The research community has risen to the challenges posed by this « evolving COVID-19 coagulopathy » and has made unprecedented efforts to promptly address its distinct characteristics. In such difficult time, both national and international societies of thrombosis and hemostasis released prompt and timely responses to guide recognition and management of COVID-19-related coagulopathy. However, latest guidelines released by the international Society on Thrombosis and Haemostasis (ISTH) on May 27, 2020, followed the American College of Chest Physicians (CHEST) on June 2, 2020 showed some discrepancies regarding thromboprophylaxis use. In this forum article, we would like to offer an updated focus on thromboprophylaxis with current incidence of VTE in ICU and non-ICU patients according to recent published studies; highlight the main differences regarding ISTH and CHEST guidelines; summarize and describe which are the key ongoing RCTs testing different anticoagulation strategies in patients with COVID-19; and finally set a proposal for COVID-19 coagulopathy specific risk factors and dedicated trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.